CXCR4 Inhibitors Could Benefit to HER2 but Not to Triple-Negative Breast Cancer Patients

Oncogene - United Kingdom
doi 10.1038/onc.2016.284
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

More Breast Cancer Patients Could Benefit From PARP Inhibitors

Cancer
Cancer ResearchOncology
2017English

Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

Oncotarget
Oncology
2014English

Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here

Cancer
Cancer ResearchOncology
2018English

Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

Triple-Negative Breast Cancer

2018English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer

PLoS ONE
Multidisciplinary
2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

SIK2 Restricts Autophagic Flux to Support Triple-Negative Breast Cancer Survival

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy